An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Quanterix to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Quanterix Corporation (NASDAQ: QTRX) will participate in a virtual fireside chat at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Nov. 18 at 8:30 a.m. EST. Executives including CEO Kevin Hrusovsky and CFO Mike Doyle will discuss advancements in biomarker analysis for precision health. A live webcast will be available on their investor relations site, with replays for 90 days post-event. Quanterix's Simoa technology aims to enhance early disease detection and improve patient care across several therapeutic areas.
Positive
None.
Negative
None.
BILLERICA, Mass.--(BUSINESS WIRE)--
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that members of its executive leadership team will participate in a virtual fireside chat discussion at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Nov. 18 at 8:30 a.m., EST. The virtual fireside chat discussion will feature Chairman and Chief Executive Officer, Kevin Hrusovsky; President of Quanterix and Diagnostics, Masoud Toloue; Chief Financial Officer, Mike Doyle and Director of Investor Relations and Business Development, Stephen Hrusovsky.
Hrusovsky will also host virtual one-on-one meetings with institutional investors that day. A live webcast of the conversation will be available on the investor section of the Quanterix website at https://ir.quanterix.com/investor-relations. Replays of the webcast will be available on the Quanterix website for 90 days following the conference.
About Quanterix Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
When is Quanterix participating in the Canaccord Genuity Forum?
Quanterix will participate in the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Nov. 18 at 8:30 a.m. EST.
Who are the executives speaking at the Quanterix event?
The executives from Quanterix participating in the event include CEO Kevin Hrusovsky, President Masoud Toloue, CFO Mike Doyle, and Director of Investor Relations Stephen Hrusovsky.
Where can I watch the Quanterix fireside chat?
The fireside chat can be watched live on the investor relations section of the Quanterix website, with replays available for 90 days following the event.
What is the main focus of Quanterix's technology?
Quanterix focuses on digitizing biomarker analysis to enhance early disease detection and improve healthcare outcomes across various therapeutic areas.
What is the stock symbol for Quanterix Corporation?
The stock symbol for Quanterix Corporation is QTRX.
